Get Live Data

The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. Glaxosmithkline Share Price
  4. Glaxosmithkline Share Regulatory News
  5. Notice of AGM

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,810.00
Bid: 1,807.50
Ask: 1,808.50
Change: 10.50 (0.58%)
Spread: 1.00 (0.055%)
Open: 1,797.00
High: 1,810.00
Low: 1,792.00
Prev. Close: 1,799.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of AGM

25 Mar 2024 13:00

RNS Number : 1907I
GSK PLC
25 March 2024

GSK plc

(the 'Company')

Publication of Notice of Annual General Meeting 2024

The Company has today published on its website (www.gsk.com/en-gb/investors/shareholder-information/annual-general-meeting/) the Notice of Annual General Meeting ('AGM') 2024 (the '2024 AGM Notice'), which will be distributed to shareholders shortly.

The Company's AGM will be held on Wednesday 8 May 2024 at 2.30pm at Royal Lancaster London, Lancaster Terrace, London W2 2TY and will also be broadcast live for shareholders to join electronically. Full details of how to join the meeting either in person or electronically are contained in the 2024 AGM Notice and AGM Guide.

In compliance with Listing Rule 9.6.1R of the UK Financial Conduct Authority's ('FCA') Listing Rules, the 2024 AGM Notice and Proxy Form for the AGM will be submitted to the FCA and will, in due course, be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

V A Whyte

Company Secretary

25 March 2024

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NOAJAMTTMTITBAI
12345678910
Date   Source Headline
3rd May 20236:00 pmRNSUS FDA approves GSK’s RSV vaccine for older adults
3rd May 20239:09 amRNSForm 8.3 - Allergy Therapeutics plc
2nd May 20233:00 pmRNSTotal Voting Rights
28th Apr 20235:01 pmRNSDirector/PDMR Shareholding
27th Apr 20237:00 amRNSGSK RSV OA vaccine gains positive EMA CHMP opinion
26th Apr 20237:00 amRNS1st Quarter Results
25th Apr 20237:00 amRNSEMA validates Jemperli filing for new indication
20th Apr 20233:30 pmRNSDirector/PDMR Shareholding
19th Apr 20233:30 pmRNSDirector/PDMR Shareholding
18th Apr 20237:00 amRNSGSK reaches agreement to acquire BELLUS Health Inc
17th Apr 20233:30 pmRNSDirector/PDMR Shareholding
17th Apr 20237:00 amRNSGepotidacin positive phase III data
3rd Apr 20233:00 pmRNSTotal Voting Rights
28th Mar 20237:00 amRNSPositive phase III RUBY results for Jemperli
27th Mar 20231:00 pmRNSPublication of 2023 AGM Notice
24th Mar 20239:59 amRNSStatement: Zantac (ranitidine) litigation
21st Mar 20233:30 pmRNSDirector/PDMR Shareholding
20th Mar 20233:30 pmRNSDirector/PDMR Shareholding
14th Mar 20237:05 amRNSPositive phase III results for MenABCWY vaccine
14th Mar 20237:00 amRNSNucala NDA accepted for review in China
13th Mar 20233:30 pmRNSDirector/PDMR Shareholding
10th Mar 20234:26 pmRNSGSK Annual Report 2022 on Form 20-F
10th Mar 202310:36 amRNSGSK publishes Annual Report 2022
2nd Mar 20237:00 amRNSFDA Ad Com votes to support GSK RSV OA vaccine
1st Mar 20233:00 pmRNSTotal Voting Rights
27th Feb 20233:30 pmRNSDirector/PDMR Shareholding
23rd Feb 20233:30 pmRNSDirector/PDMR Shareholding
23rd Feb 20237:00 amRNSViiV Healthcare announces Cabenuva positive data
22nd Feb 20233:30 pmRNSDirector/PDMR Shareholding
16th Feb 20237:00 amRNSNEJM publishes GSK RSV OA vaccine candidate trial
15th Feb 20234:04 pmRNSDirector/PDMR Shareholding
15th Feb 20234:00 pmRNSDirector/PDMR Shareholding
14th Feb 20237:00 amRNSDirector/PDMR Shareholding
14th Feb 20237:00 amRNSDirector/PDMR Shareholding
14th Feb 20237:00 amRNSDirector/PDMR Shareholding
14th Feb 20237:00 amRNSDirector/PDMR Shareholding
13th Feb 20235:35 pmRNSEMTN Notes repurchase results
10th Feb 20233:30 pmRNSDirector/PDMR Shareholding
10th Feb 20237:05 amRNSJemperli full FDA approval following GARNET trial
10th Feb 20237:00 amRNSJemperli FDA ODAC positive outcome
2nd Feb 20237:00 amRNSDaprodustat approved by US FDA for anaemia of CKD
1st Feb 20233:30 pmRNSDirector/PDMR Shareholding
1st Feb 20233:00 pmRNSTotal Voting Rights
1st Feb 20237:05 amRNSBenlysta granted Orphan Drug Designation by US FDA
1st Feb 20237:00 amRNSFinal Results
18th Jan 20233:30 pmRNSDirector/PDMR Shareholding
17th Jan 20233:30 pmRNSDirector/PDMR Shareholding
16th Jan 20233:30 pmRNSDirector/PDMR Shareholding
13th Jan 20233:30 pmRNSDirector/PDMR Shareholding
12th Jan 20233:30 pmRNSDirector/PDMR Shareholding
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.